Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Biocure Technology Inc C.CURE.X

Alternate Symbol(s):  BICTF

Healthcare Biotechnology
Biocure Technology Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of its own CAR T-cell therapy, targeting Chronic lymphocytic leukemia and solid tumor cancers. Additionally, the Company is developing biosimilar technologies for cancer treatment. The Company’s products include Interferon Beta, Ranibizumab and PEG-Filgrastim.


CSE:CURE.X - Post by User

Biocure Technology Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Post by sailor1986on Oct 16, 2018 3:13pm
221 Views
Post# 28812567

Great News but nobody is buying.

Great News but nobody is buying. Sounds very promising to treat cancer. Is there anyone who can shed more light on this discovery. This could be huge but why nobody is paying attention?
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities